Comments
Strides Pharma Science has received USFDA approval for its greenfield oral dosage facility in Singapore.
With the commercialization of its manufacturing facility in Singapore, Strides will join the league of global pharmaceutical companies having a manufacturing and Research and Development footprint in Singapore. Further, the facility will complement Strides’ existing manufacturing base and will help meet increased demand from its fast-growing regulated markets business across US, Australia, UK and Europe, the company said in a statement.
Since Singapore is also amongst the list of designated countries under the Trade Agreements Act (TAA) making it eligible to supply goods under Federal Supply Schedule (FSS) contracts in the US, the manufacturing facility will enable Strides to tap opportunities under various federal government procurement initiatives.
Strides also said that the facility operating at its peak capacity will produce 1.4 billion tablets and hard gelatin capsules and has already been approved by Health Science Authority (HSA) Singapore and Therapeutic Goods Administration (TGA) Australia.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.